Senolytics for Secondary Progressive MS

Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis

Not yet recruitingPhase 1Progressive MSNCT07270120

What it found

Still running

No result yet.

What was tested

Treatment tested

  • Dasatinib anhydrous

    Bcr/Abl fusion protein inhibitor|Ephrin type-A receptor 2 inhibitor|Platelet-derived growth factor receptor beta inhibitor|SRC inhibitor|Stem cell growth factor receptor inhibitor|Tyrosine-protein kinase ABL inhibitor

What it measured

Main measures

  • Participant retention rate

    Baseline until 3 months

    Feasibility

  • Recruitment feasibility

    Baseline

    Feasibility

  • Frequency of adverse drug effects of dasatinib and quercetin

    From baseline through study completion at 1 year

Who could take part

Progressive MS · 50 to 85

Show the full criteria

Inclusion criteria

1. Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria 2. Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone. 3. Evidence of MS progression over the past 12 months.

Exclusion criteria

1. Unstable coronary artery disease (myocardial infarction within 6 months or angina) 2. Hospitalization within 6 months 3. Stroke or transient ischemic attack in the past 6 months 4. Pulmonary arterial hypertension 5. Current or chronic history of liver disease 6. Alzheimer's or Parkinson's disease 7. Drug or alcohol abuse in the previous 5 years 8. History of coagulation disorders, central nervous system hemorrhage, or gastrointestinal hemorrhage 9. History of angina or myocardial infarction, arrhythmia, or heart failure at any time 10. QTc prolongation 11. Anemia (Hgb\<9), thrombocytopenia (platelets\<50,000 per microliter), or neutropenia (ANC\< 1000 per microliter) 12. Moderate hypokalemia (2.9 mmol/L) and moderate hypomagnesemia (0.9-1.1 mg/dL or 0.37-0.45 mmol/L) 13. ALT/AST >1.5x ULN, total bilirubin >ULN, and alkaline phosphatase >2x ULN 14. Chronic renal disease (glomerular filtration rate \< 30 mL/min/1.73 m2) 15. Alcohol intake greater than 2 drinks/day for men and greater than 1 drink/day for women 16. Anti-arrhythmic medications known to cause QTc prolongation 17. Antipsychotics and anxiolytics 18. Anti-platelet or anti-coagulant medications other than aspirin 19. Quinolone antibiotics 20. Pregnant or lactating subjects or subjects intending to become pregnant or to donate egg/sperm 21. Participants with p16INK4a below the median of SPMS patients in the OSU Aging and MS Cohort 22. Use of drugs metabolized by the same liver enzymes as D or Q

As registered. Criteria can change, so ask the trial team or your neurologist.

Contact details on the registry

About this trial

In the sponsor's words

This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.

Papers

    Loading reviews and guidelines…

    History

      1. Started

        Jan 2026

      2. Main results due

        Jan 2027

      3. Finished

        Jan 2028

      Assembled by software from public sources.